Australia’s ProTA accelerates the development of immunotherapy to treat peanut allergy
Allergy immunotherapy company ProTA Therapeutics Pty Ltd (ProTA) will accelerate the development of a possible treatment for life-threatening peanut allergy with the appointment of its new CEO. ProTA has appointed former Mesoblast Vice President Operations Dr. Suzanne Lipe,…
Opthea Successfully Completes Placement and Institutional Entitlement Offer
• Placement and Institutional Entitlement Offer successfully completed, raising approximately A$42million with strong support from both existing and new institutional and sophisticated investors • Retail Entitlement Offer will open on Monday, 10 April 2017 and closes at 5:00pm…
Bionic Vision Technologies raises $US18m from State Path Capital, China Huarong
The Australian university-owned company in the race to develop a bionic eye to restore sight has been saved from its own near plunge into darkness after raising $US18 million ($23.6 million) from Chinese investors including the nephew of Hong…
The Medical Technologies and Pharmaceuticals (MTP) Roadmap – unlocking future growth opportunities for Australia
A changing global landscape The global MTP industry is on the cusp of enormous growth globally due to a range of factors including ageing populations, the growth of emerging markets seeking better health services and unprecedented innovation in…
New abilities to enhance cancer research at the Australian Synchrotron
It gave me great pleasure to today unveil the newest research tool that Australian scientists and researchers have in the fight against cancer. The Australian Synchrotron’s new multi-million dollar Australian Cancer Research Foundation (ACRF) Detector will fast-track new…
Easing the pain of global expansion
Two years after going global, Australian healthcare company Medical Developments International (MDI) which manufactures the acute pain killer Penthrox (commonly known as ‘the green whistle’) has opened a new facility in Melbourne Assisted by CSIRO, MDI has seen…
Opthea Launches A$45 Million Financing to Progress OPT- 302 Expanded Clinical Development
Opthea Limited (ASX:OPT) (“Opthea”), a developer of novel biologic therapies for the treatment of eye diseases, today announced the launch of an entitlement offer and institutional placement (collectively the “Offer”) to raise approximately A$45 million. Proceeds from the…
Lab-grown mini-organs help model disease, test new drugs
To the naked eye, the little globs of cells are undifferentiated masses, smaller than sesame seeds. Put them under a microscope, though, and these lab-grown miniature organs show striking complexity: the tiny tubules of a kidney, the delicate…
Australia’s new National Science Statement! The Australian Government long-term vision for science research and policy making
The Australian Government’s National Innovation and Science Agenda identified science as one of the critical elements for Australia to deliver new sources of growth, maintain high‑wage jobs and seize the next wave of economic prosperity. Science—including the natural,…
Bone, cartilage and tissue; we’ve cracked the trifecta (and it’s made of titanium and plastic)
We’ve been quietly working away in Melbourne on something big. The big trifecta of a bone, cartilage and tissue implant. The first of its kind. More specifically, a 3D printed titanium and polymer sternum to suit individual patients. …
The US drug pricing debate: Managing risks to results
EY report on drug pricing The unsustainable trajectory of the health care spending in the US is generating much dialog and consternation across a variety of stakeholders including governments, industry, media academic think-tanks and the general public. Prescription…
New Director of Bio 21 announced
Professor Michael Parker has been appointed as the new Director of the University of Melbourne’s Bio 21 Molecular Science and Biotechnology Institute. One of Australia’s leading protein structural biologists, Prof Parker will take up the role as part…
